Most Recent Articles about PFE
Ocular's Glaucoma Drug Study Fails to Meet Primary Endpoint http://www.zacks.com/stock/news/417631/oculars-glaucoma-drug-study-fails-to-meet-primary-endpoint?cid=CS-ZC-FT-417631 May 21, 2019 - Ocular's (OCUL) phase III study on OTX-TP for the reduction of intraocular pressure (IOP) in patients with primary open-angle glaucoma fails to achieve primary endpoint.
Pharma Stock Roundup: FDA Okays Line Extensions of LLY, PFE, ABBV Cancer Drugs http://www.zacks.com/stock/news/415516/pharma-stock-roundup-fda-okays-line-extensions-of-lly-pfe-abbv-cancer-drugs?cid=CS-ZC-FT-415516 May 17, 2019 - FDA grants approval for line extensions of Lilly (LLY), Pfizer (PFE) and Roche (RHHBY)/AbbVie's (ABBV) cancer drugs
Pfizer's Eczema Candidate Meets All Goals in Phase III Study http://www.zacks.com/stock/news/414939/pfizers-eczema-candidate-meets-all-goals-in-phase-iii-study?cid=CS-ZC-FT-414939 May 16, 2019 - Pfizer's (PFE) investigational eczema treatment abrocitinib succeeds in pivotal late-stage study.

Related Companies

Name Exchange Price Mkt Cap
NVS Novartis AG NYSE $85.13 $197.65B
MRK Merck & Company, Inc. NYSE $70.42 $187.28B
ABBV AbbVie Inc. NYSE $95.37 $144.42B
JNJ Johnson & Johnson NYSE $139.96 $375.48B
ABT Abbott Laboratories NYSE $67.67 $118.71B
Sector: Health Care > Industry: Major Pharmaceuticals